Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60373 | 0.84 | MAPK1 (0.68) | TDP1MAPK1CYP3A4TRPA1TSHR | |
| SCHEMBL29794124 | 0.84 | MAPK1 (0.68) | TDP1MAPK1CYP3A4TRPA1TSHR | |
| O-Xylene SCHEMBL27865799 | 0.82 | MAPK1 (0.76) | TDP1MAPK1CYP3A4TRPA1TSHR | |
| SCHEMBL58874 | 0.81 | MAPK1 (1.00) | TDP1MAPK1CYP3A4TRPA1TSHR | |
| SCHEMBL29376406 | 0.81 | MAPK1 (1.00) | TDP1MAPK1CYP3A4TRPA1TSHR | |
| SCHEMBL58809 | 0.81 | CYP3A4 (0.70) | TDP1MAPK1CYP3A4TRPA1TSHR | |
| SCHEMBL11574824 | 0.80 | TDP1 (0.42) | TDP1MAPK1CYP3A4TRPA1TSHR | |
| SCHEMBL667517 | 0.79 | CYP3A4 (0.62) | TDP1MAPK1CYP3A4TRPA1TSHR | |
| Dimethylamine SCHEMBL11830270 | 0.78 | MAPK1 (0.85) | TDP1MAPK1CYP3A4TRPA1TSHR | |
| SCHEMBL49899 | 0.78 | TDP1 (0.70) | TDP1MAPK1CYP3A4TRPA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119186531-A | Chiral stationary phase derivatized by multi-functional hydroxypropyl-beta-cyclodextrin, preparation method and application thereof | 浙江工业大学 | 2024-12-27 | — | — | CN | claimed |
| CN-112375226-B | Bonded amylose derivative and preparation method and application thereof | 苏州纳微科技股份有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-115386245-A | Preparation method and application of lipophilic carbon nitride nanosheet | 浙江理工大学 | 2022-11-25 | — | — | CN | claimed |
| CN-112375226-A | Bonded amylose derivative and preparation method and application thereof | 苏州纳微科技股份有限公司 | 2021-02-19 | — | — | CN | claimed |
| CN-119186531-A | Chiral stationary phase derivatized by multi-functional hydroxypropyl-beta-cyclodextrin, preparation method and application thereof | 浙江工业大学 | 2024-12-27 | — | — | CN | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-112375226-B | Bonded amylose derivative and preparation method and application thereof | 苏州纳微科技股份有限公司 | 2023-03-17 | — | — | CN | disclosed |
| WO-2022200857-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| CN-114950393-A | Coating type polysaccharide derivative chiral stationary phase and preparation method thereof | 江苏纯安科技有限公司 | 2022-08-30 | — | — | CN | disclosed |
| EP-4041231-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-08-04 | — | — | US | disclosed |
| EP-0371240-B1 | USE OF N-PHENYL-SUBSTITUTED OXAZINDIONES AS HERBICIDES AND N-PHENYL-SUBSTITUTED OXAZINDIONES AND SOME PROCESSES FOR THEIR PRODUCTION | BAYER AG (DE) | 1993-06-16 | — | — | EP | disclosed |
| US-5164498-A | Herbicidal N-phenyl-substituted oxazinediones | BAYER AKTIENGESELLSCHAFT (DE) | 1992-11-17 | — | — | US | disclosed |
| EP-0241559-B1 | OXAZOLIDINEDIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING THE SAME | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-10-30 | — | — | EP | disclosed |
| US-4983751-A | Chemical intermediates | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-01-08 | — | — | US | disclosed |
| EP-0371240-A1 | Use of N-phenyl-substituted oxazindiones as herbicides and N-phenyl-substituted oxazindiones and some processes for their production | BAYER AG (DE) | 1990-06-06 | — | — | EP | disclosed |
| US-4818272-A | NONPHYTOTOXICITY FOR CROPS HELICAL STREAMS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1989-04-04 | — | — | US | disclosed |
| EP-0241559-A1 | OXAZOLIDINEDIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND HERBICIDES CONTAINING THE SAME | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1987-10-21 | — | — | EP | disclosed |
| US-3961061-A | INSECTICIDES, FUNGICIDES, BACTERICIDES, MITICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | TDP1 1868/4885MAPK1 3358/4885CYP3A4 3128/4885 |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | AOC2, AOC3, INF2 | TDP1 4323/4885MAPK1 3104/4885CYP3A4 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.